Monoclonal antibody provides strong real-world protection against severe RSV in infants, suggests meta-analysis

An Andalusian research has certified the usefulness of the medicine nirsevimab against the syncitial respiratory virus (SVR) in babies, and its impact on reducing the severity of infections.The study has involved hospitals from all over the region, in collaboration with the University of Granada (UGR) and the General Directorate of Public Health of the Health and Consumer Department.The study indicates that, although children receiving nirsevima…

Beyfortus, a treatment intended to immunize babies against the main virus causing bronchiolite, is very effective in preventing serious infections with respiratory syncytial virus (VRS) in infants, confirms a wide analysis published Friday.

A meta-analysis, published on Friday by the magazine "The Lancet Child & Adolescent Health", reveals that nirsevimab, the molecule of this innovative treatment, reduces the risk of hospitalization of children 12 months of age or younger by 83% on average.

Nirsevimab, the name of the molecule, is not a vaccine even if it is injected, but a preventive treatment that prevents the virus from infecting the body.

Monoclonal antibody provides strong real-world protection against severe RSV in infants, suggests meta-analysis

Nirsevimab, a monoclonal antibody, is highly effective in real-world conditions at preventing severe respiratory syncytial virus (RSV) infections in infants, suggests a meta-analysis published in The Lancet Child & Adolescent Health journal.

RSV Vaccines for the Youngest and the Oldest: A Public Health Milestone—and a Public Trust Test

After decades of research and anticipation, the medical community is celebrating a significant breakthrough: the arrival of respiratory syncytial virus (RSV) vaccines designed specifically for the two groups most vulnerable to severe disease—infants and older adults. Approved by the U.S. Food and Drug Administration (FDA) in late 2024, these vaccines represent a milestone in infectious disease prevention. Yet their success story is far from guar…